Twist Bioscience, Boehringer Ingelheim Joins Forces For Antibody Research Programs

by Vandana Singh, Benzinga Editor

September 9, 2021 10:52 AM | 1 min read | Make a Comment

Twist Bioscience Corporation TWST has announced a broad-based research collaboration with Boehringer Ingelheim International GmbH.
The collaboration will use Twist's proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim.
Boehringer Ingelheim retains exclusive worldwide rights to develop and commercialize any therapeutic antibodies discovered as part of the collaboration.
Twist will receive an upfront payment for each program entry. In addition, Twist can earn up to $710 million in milestone payments for the multiple target discovery programs.
Price Action: TWST shares are up 7.50% at $119.32 during the market session on the last check Thursday.

Posted In: Biotech Long Ideas News Health Care Contracts Movers Trading Ideas General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.